These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 32750548)

  • 1. Mixed-beam approach for high-risk prostate cancer: Carbon-ion boost followed by photon intensity-modulated radiotherapy. Dosimetric and geometric evaluations (AIRC IG-14300).
    Gugliandolo SG; Marvaso G; Comi S; Pepa M; Romanò C; Zerini D; Augugliaro M; Russo S; Vischioni B; Valvo F; Giandini T; Avuzzi B; Valdagni R; Ciardo D; De Cobelli O; Jereczek-Fossa BA; Cattani F; Orecchia R
    Phys Med; 2020 Aug; 76():327-336. PubMed ID: 32750548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a commercial DIR platform for contour propagation in prostate cancer patients treated with IMRT/VMAT.
    Hammers JE; Pirozzi S; Lindsay D; Kaidar-Person O; Tan X; Chen RC; Das SK; Mavroidis P
    J Appl Clin Med Phys; 2020 Feb; 21(2):14-25. PubMed ID: 32058663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II multi-institutional clinical trial on a new mixed beam RT scheme of IMRT on pelvis combined with a carbon ion boost for high-risk prostate cancer patients.
    Marvaso G; Jereczek-Fossa BA; Vischioni B; Ciardo D; Giandini T; Hasegawa A; Cattani F; Carrara M; Ciocca M; Bedini N; Villa S; Morlino S; Russo S; Zerini D; Colangione SP; Panaino CMV; Fodor C; Santoro L; Pignoli E; Valvo F; Valdagni R; De Cobelli O; Orecchia R
    Tumori; 2017 May; 103(3):314-318. PubMed ID: 28009421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dosimetric comparison of high-dose-rate brachytherapy and intensity-modulated radiation therapy as a boost to the prostate.
    Hermesse J; Biver S; Jansen N; Lenaerts E; Nickers P
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):269-76. PubMed ID: 19775833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous integrated intensity-modulated radiotherapy boost for locally advanced gynecological cancer: radiobiological and dosimetric considerations.
    Guerrero M; Li XA; Ma L; Linder J; Deyoung C; Erickson B
    Int J Radiat Oncol Biol Phys; 2005 Jul; 62(3):933-9. PubMed ID: 15936580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of on-board kV cone beam computed tomography-based dose calculation with deformable image registration using Hounsfield unit modifications.
    Onozato Y; Kadoya N; Fujita Y; Arai K; Dobashi S; Takeda K; Kishi K; Umezawa R; Matsushita H; Jingu K
    Int J Radiat Oncol Biol Phys; 2014 Jun; 89(2):416-23. PubMed ID: 24685445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of a deformable image registration technique for cone beam CT-based dose verification.
    Moteabbed M; Sharp GC; Wang Y; Trofimov A; Efstathiou JA; Lu HM
    Med Phys; 2015 Jan; 42(1):196-205. PubMed ID: 25563260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical toxicities and dosimetric parameters after whole-pelvis versus prostate-only intensity-modulated radiation therapy for prostate cancer.
    Deville C; Both S; Hwang WT; Tochner Z; Vapiwala N
    Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):763-72. PubMed ID: 20171807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of radiation therapy for locally advanced adenoid cystic carcinomas with infiltration of the skull base using photon intensity-modulated radiation therapy (IMRT) and a carbon ion boost.
    Schulz-Ertner D; Didinger B; Nikoghosyan A; Jäkel O; Zuna I; Wannenmacher M; Debus J
    Strahlenther Onkol; 2003 May; 179(5):345-51. PubMed ID: 12740662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment planning comparison of IMPT, VMAT and 4π radiotherapy for prostate cases.
    Tran A; Zhang J; Woods K; Yu V; Nguyen D; Gustafson G; Rosen L; Sheng K
    Radiat Oncol; 2017 Jan; 12(1):10. PubMed ID: 28077128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dosimetric comparison of tomotherapy and volumetric modulated arc therapy in the treatment of high-risk prostate cancer with pelvic nodal radiation therapy.
    Pasquier D; Cavillon F; Lacornerie T; Touzeau C; Tresch E; Lartigau E
    Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):549-54. PubMed ID: 22677369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosimetric study of pelvic proton radiotherapy for high-risk prostate cancer.
    Chera BS; Vargas C; Morris CG; Louis D; Flampouri S; Yeung D; Duvvuri S; Li Z; Mendenhall NP
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):994-1002. PubMed ID: 19619961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiotherapy treatment plans with RapidArc for prostate cancer involving seminal vesicles and lymph nodes.
    Yoo S; Wu QJ; Lee WR; Yin FF
    Int J Radiat Oncol Biol Phys; 2010 Mar; 76(3):935-42. PubMed ID: 20044214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Organ-sparing Intensity-modulated radiotherapy for anal cancer using the ACTII schedule: a comparison of conventional and intensity-modulated radiotherapy plans.
    Brooks CJ; Lee YK; Aitken K; Hansen VN; Tait DM; Hawkins MA
    Clin Oncol (R Coll Radiol); 2013 Mar; 25(3):155-61. PubMed ID: 22981970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosimetric advantages of IMRT simultaneous integrated boost for high-risk prostate cancer.
    Li XA; Wang JZ; Jursinic PA; Lawton CA; Wang D
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1251-7. PubMed ID: 15752907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical application of high-dose, image-guided intensity-modulated radiotherapy in high-risk prostate cancer.
    Bayley A; Rosewall T; Craig T; Bristow R; Chung P; Gospodarowicz M; Ménard C; Milosevic M; Warde P; Catton C
    Int J Radiat Oncol Biol Phys; 2010 Jun; 77(2):477-83. PubMed ID: 19733014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A treatment planning and acute toxicity comparison of two pelvic nodal volume delineation techniques and delivery comparison of intensity-modulated radiotherapy versus volumetric modulated arc therapy for hypofractionated high-risk prostate cancer radiotherapy.
    Myrehaug S; Chan G; Craig T; Weinberg V; Cheng C; Roach M; Cheung P; Sahgal A
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e657-62. PubMed ID: 22245189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dominant intraprostatic lesion boosting in sexual-sparing radiotherapy of prostate cancer: A planning feasibility study.
    Ciabatti S; Ntreta M; Buwenge M; Gaudiano C; Sessagesimi E; Romani F; Angelini AL; Cammelli S; Macchia G; Deodato F; Zamagni A; Golfieri R; Morganti AG; Cilla S
    Med Dosim; 2019 Winter; 44(4):356-364. PubMed ID: 30955990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of organ motion on conformal vs. intensity-modulated pelvic radiotherapy for prostate cancer.
    Hysing LB; Skorpen TN; Alber M; Fjellsbø LB; Helle SI; Muren LP
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1496-503. PubMed ID: 18538493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the availability of single-position treatment with a rotating gantry and the validity of deformable image registration dose assessment for pancreatic cancer carbon-ion radiotherapy.
    Miyasaka Y; Kawashiro S; Lee SH; Souda H; Ichikawa M; Chai H; Ishizawa M; Ono T; Sato H; Iwai T
    J Appl Clin Med Phys; 2024 Jun; 25(6):e14330. PubMed ID: 38478368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.